Get started
BLUEPRINT MEDICINES CORP COM USD0.001BLUEPRINT MEDICINES CORP COM USD0.001BLUEPRINT MEDICINES CORP COM USD0.001

BLUEPRINT MEDICINES CORP COM USD0.001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0HOJ chart


Full chart

0HOJ upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.76 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.06 USD
Net income (FY)
‪−506.98 M‬ USD
Revenue (FY)
‪249.38 M‬ USD
Shares float
‪62.37 M‬
Beta (1Y)
1.41

Employees


Employees (FY)
655
Change (1Y)
+14 +2.18%
Revenue / Employee (1Y)
‪380.73 K‬ USD
Net income / Employee (1Y)
‪−774.02 K‬ USD

About Blueprint Medicines Corporation


Sector
Health Technology
Industry
Biotechnology
CEO
Kathryn Haviland
Website
blueprintmedicines.com
Headquarters
Cambridge
Founded
2008
FIGI
BBG00JWMZ149
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0HOJ news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0HOJ is 92.14 USD — it has increased by 2.89% in the past 24 hours. Watch BLUEPRINT MEDICINES CORP COM USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange BLUEPRINT MEDICINES CORP COM USD0.001 stocks are traded under the ticker 0HOJ.
0HOJ stock has risen by 10.56% compared to the previous week, the month change is a 4.48% rise, over the last year BLUEPRINT MEDICINES CORP COM USD0.001 has showed a 53.55% increase.
We've gathered analysts' opinions on BLUEPRINT MEDICINES CORP COM USD0.001 future price: according to them, 0HOJ price has a max estimate of 167.00 USD and a min estimate of 81.00 USD. Watch 0HOJ chart and read a more detailed BLUEPRINT MEDICINES CORP COM USD0.001 stock forecast: see what analysts think of BLUEPRINT MEDICINES CORP COM USD0.001 and suggest that you do with its stocks.
0HOJ reached its all-time high on Jul 16, 2024 with the price of 121.20 USD, and its all-time low was 38.46 USD and was reached on Feb 24, 2023. View more price dynamics on 0HOJ chart.
See other stocks reaching their highest and lowest prices.
0HOJ stock is 3.32% volatile and has beta coefficient of 1.41. Track BLUEPRINT MEDICINES CORP COM USD0.001 stock price on the chart and check out the list of the most volatile stocks — is BLUEPRINT MEDICINES CORP COM USD0.001 there?
Today BLUEPRINT MEDICINES CORP COM USD0.001 has the market capitalization of ‪5.84 B‬, it has increased by 7.40% over the last week.
Yes, you can track BLUEPRINT MEDICINES CORP COM USD0.001 financials in yearly and quarterly reports right on TradingView.
BLUEPRINT MEDICINES CORP COM USD0.001 is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
0HOJ earnings for the last quarter are −0.89 USD per share, whereas the estimation was −0.96 USD resulting in a 7.40% surprise. The estimated earnings for the next quarter are −0.68 USD per share. See more details about BLUEPRINT MEDICINES CORP COM USD0.001 earnings.
BLUEPRINT MEDICINES CORP COM USD0.001 revenue for the last quarter amounts to ‪128.20 M‬ USD, despite the estimated figure of ‪127.56 M‬ USD. In the next quarter, revenue is expected to reach ‪146.21 M‬ USD.
0HOJ net income for the last quarter is ‪−56.28 M‬ USD, while the quarter before that showed ‪−49.99 M‬ USD of net income which accounts for −12.57% change. Track more BLUEPRINT MEDICINES CORP COM USD0.001 financial stats to get the full picture.
No, 0HOJ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 655.00 employees. See our rating of the largest employees — is BLUEPRINT MEDICINES CORP COM USD0.001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BLUEPRINT MEDICINES CORP COM USD0.001 EBITDA is ‪−262.13 M‬ USD, and current EBITDA margin is −190.32%. See more stats in BLUEPRINT MEDICINES CORP COM USD0.001 financial statements.
Like other stocks, 0HOJ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BLUEPRINT MEDICINES CORP COM USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BLUEPRINT MEDICINES CORP COM USD0.001 technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BLUEPRINT MEDICINES CORP COM USD0.001 stock shows the buy signal. See more of BLUEPRINT MEDICINES CORP COM USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.